Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study to Assess the Effects of Allergic Rhinitis and Coadministration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine

Next Previous
Search
Trial Profile

An Open-label Study to Assess the Effects of Allergic Rhinitis and Coadministration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary) ; Esketamine (Primary) ; Mometasone; Oxymetazoline
  • Indications Allergic rhinitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 10 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top